Long-term persistence with anti-osteoporosis drugs after fracture

Osteoporosis International

Volumn 26, Issue 6, 2015, Pages 1831-1840

  Klop, C ^a   Welsing, P M J ^b   Elders, P J M ^c   Overbeek, J A ^d   Souverein, P C ^a   Burden, A M ^a,e   van Onzenoort, H A W ^e,g   Leufkens, H G M ^a   Bijlsma, J W J ^b   de Vries, F ^a,e,f  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epidemiology; Fracture prevention; Osteoporosis; Persistence; Therapeutics

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FOREARM FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; SPINE FRACTURE; SURVIVAL TIME; TREATMENT DURATION; VERY ELDERLY; DRUG ADMINISTRATION; FACTUAL DATABASE; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; NETHERLANDS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PROCEDURES; RECURRENT DISEASE; SECONDARY PREVENTION; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NETHERLANDS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RECURRENCE; SECONDARY PREVENTION;

EID: 84931006187     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-015-3084-3     Document Type: Article

References (50)

1. Kanis JA, Johnell O (1999) The burden of osteoporosis. J Endocrinol Investig 22:583–588
2. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB et al (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323
3. Van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ (2009) Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis 68:99–102
4. Huntjens KMB, Kosar S, van Geel TACM, Geusens PP, Willems P, Kessels A et al (2010) Risk of subsequent fracture and mortality within 5 years after a non-vertebral fracture. Osteoporos Int 21:2075–2082
5. Gibson-Smith D, Klop C, Elders PJ, Welsing PM, van Schoor N, Leufkens HG et al (2014) The risk of major and any (non-hip) fragility fracture after hip fracture in the United Kingdom: 2000–2010. Osteoporos Int 25:2555–2563
6. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1, CD001155
7. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V et al (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1, CD004523
8. National Institute for Health and Clinical Excellence (NICE) (2008) Systematic reviews of clinical effectiveness prepared for the guideline ‘Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk’.https://www.nice.org.uk/guidance/cg146/documents/osteoporosis-evidence-reviews2. Accessed 16 Sept 2014
9. Ross S, Samuels E, Gairy K, Iqbal S, Badamgaray E, Siris E (2011) A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14:571–581
10. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T (2012) GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 23:223–31
11. Sampalis JS, Adachi JD, Rampakakis E, Vaillancourt J, Karellis A, Kindundu C (2012) Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 27:202–10
12. Meijer WM, Penning-van Beest FJA, Olson M, Herings RMC (2008) Relationship between duration of compliant bisphosphonate use and the risk of osteoporotic fractures. Curr Med Res Opin 24:3217–3222
13. Netelenbos JC, Geusens PP, Ypma G, Buijs SJE (2011) Adherence and profile of non-persistence in patients treated for osteoporosis – a large-scale, long-term retrospective study in the Netherlands. Osteoporos Int 22:1537–46
14. Li L, Roddam A, Gitlin M, Taylor A, Shepherd S, Shearer A et al (2012) Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database. Menopause 19:33–40
15. Van Boven JFM, de Boer PT, Postma MJ, Vegter S (2013) Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab 31:562–570
16. Penning-van Beest FJA, Goettsch WG, Erkens JA, Herings RMC (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28:236–42
17. Confavreux CB, Canoui-Poitrine F, Schott A, Ambrosi V, Tainturier V, Chapurlat RD (2012) Persistence at 1 year of oral antiosteoporitic drugs: a prospective study in a comprehensive health insurance database. Eur J Endocrinol 166:735–741
18. Balasubramanian A, Brookhart MA, Goli V, Critchlow CW (2013) Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women. Int J Gen Med 6:839–848
19. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493–501. doi:10.1016/S0025-6196(11)61093-8
20. Cramer JA, Gold DT, Silverman SL, Lewiecki EM (2007) A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18:1023–31. doi:10.1007/s00198-006-0322-8
21. Buurma H, Bouvy ML, De Smet PA, Floor-Schreudering A, Leufkens HG, Egberts AC (2008) Prevalence and determinants of pharmacy shopping behavior. J Clin Pharm Ther 33:17–23
22. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691–705
23. Gardarsdottir H, Souverein PC, Egberts TCG, Heerdink ER (2010) Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. J Clin Epidemiol 63:422–427
24. Geers HC, Bouvy ML, Heerdink ER (2011) Estimates of statin discontinuation rates are influenced by exposure and outcome definitions. Ann Pharmacother 45:576–81
25. Eekman DA, van Helden H, Huisman AM, Verhaar HJJ, Bultink IEM, Geusens PP et al (2013) Optimizing fracture prevention: the fracture liaison service, an observational study. Osteoporos Int. doi:10.1007/s00198-013-2481-8
26. Boudou L, Gerbay B, Chopin F, Ollagnier E, Collet P, Thomas T (2011) Management of osteoporosis in fracture liaison service associated with long-term adherence to treatment. Osteoporos Int 22:2099–2106
27. Ojeda-Bruno S, Naranjo A, Francisco-Hernández F, Erausquin C, Rúa-Figueroa I, Ouevedo C et al (2011) Secondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonates. Osteoporos Int 22:1821–1828
28. Dehamchia-Rehailia N, Ursu D, Henry-Desailly I, Fardellone P, Paccou J (2014) Secondary prevention of osteoporotic fractures: evaluation of the Amiens University Hospital’s fracture liaison service between January 2010 and December 2011. Osteoporos Int 25:2409–2416
29. Ganda K, Schaffer A, Pearson S, Seibel MJ (2014) Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management. Osteoporos Int 25:1345–1355
30. Roerholt C, Eiken P, Abrahamsen B (2009) Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int 20:299–307
31. Sewerynek E, Horst-Sikorska H, Stepien-Klos W, Antkowiak A, Janik M, Cieslak K et al (2013) The role of counseling and other factors in compliance of postmenopausal osteoporotic patients to alendronate 70 therapy. Arch Med Sci 9:288–296
32. McHorney CA, Schousboe JT, Cline RR, Weiss TW (2007) The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 23:3137–3152
33. Salter C, McDaid L, Bhattacharya D, Holland R, Marshall T, Howe A (2014) Abandoned acid? Understanding adherence to bisphosphonate medications for the prevention of osteoporosis among older women: a qualitative longitudinal study. PLoS ONE 9:e83552. doi:10.1371/journal.pone.0083552
34. Brookhart MA, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM et al (2007) Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 120:251–6
35. Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922–928
36. Burden AM, Paterson JM, Solomon DH, Mamdani M, Juurlink DN, Cadarette SM (2012) Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int 23:1075–82. doi:10.1007/s00198-011-1645-7
37. Ström O, Landfeldt E, Garellick G (2015) Residual effect after oral bisphosphonate treatment and healthy adherer effects-the Swedish adherence register analysis (SARA). Osteoporos Int 26:315–325
38. Grymonpre R, Cheang M, Fraser M, Metge C, Sitar DS (2006) Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 44:471–477
39. Lau HS, de Boer A, Beuning KS, Porsius A (1997) Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 50:619–625
40. Morin SN, Lix LM, Leslie WD (2014) The importance of previous fracture site on osteoporosis diagnosis and incident fractures in women. J Bone Miner Res 29:1675–1680
41. Schuit SC, van der Klift M, Weel AE, de Laet CE, Burger H, Seeman E et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202
42. Kim SH, Szabo RM, Marder RA (2008) Epidemiology of humerus fractures in the United States: nationwide emergency department sample. Arthritis Care Res 64:407–414
43. Peeters G, Tett SE, Duncan EL, Mishra GD, Dobson AJ (2014) Osteoporosis medication dispensing for older Australian women from 2002 to 2010: influences of publications, guidelines, marketing activities and policy. Pharmacoepidemiol Drug Saf. doi:10.1002/pds.3703
44. Curtis JR, Cai Q, Wade SW, Stolshek BS, Adams JL, Balasubramanian A et al (2013) Osteoporosis medication adherence: physician perceptions vs. patient’s utilization. Bone 55:1–6
45. Shu AD, Stedman MR, Polinski JM, Jan SA, Patel M, Truppo C et al (2009) Adherence to osteoporosis medications after patient and physician brief education: post hoc analysis of a randomized controlled trial. Am J Manage Care 15:417–424
46. Solomon DH, Iversen MD, Avorn J, Gleeson T, Brookhart MA, Patrick AR et al (2012) Osteoporosis telephonic intervention to improve medication regimen adherence. A large, pragmatic, randomized controlled trial. Arch Intern Med 172:477–483
47. Stuurman-Bieze AGG, Hiddink EG, van Boven JFM, Vegter S (2014) Proactive pharmaceutical care interventions decrease patient’s nonadherence to osteoporosis medication. Osteoporos Int 25:1807–1812
48. Van Boven JFM, Hiddink EG, Stuurman-Bieze AGG, Postma MJ, Vegter S (2011) Gestructureerde medicatiebegeleiding om de therapietrouw bij bisphosphonaten te verbeteren biedt kansen voor kosteneffectieve farmaceutische patientenzorg. PW Wetenschappelijk Platform 5:a1132
49. Montori VM, Shah ND, Pencille LJ, Branda ME, van Houten HK, Swiglo BA et al (2011) Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. Am J Med 124:549–556
50. Hiligsmann M, Salas M, Hughes DA, Manias E, Gwadry-Sridhar FH, Linck P et al (2013) Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int 24:2907–2918